|Bid||66.59 x 1000|
|Ask||67.50 x 800|
|Day's Range||66.16 - 69.70|
|52 Week Range||26.40 - 74.81|
|Beta (3Y Monthly)||-0.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||82.38|
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (30-Year Financial, Insider Trades) Brian B Hansen (insider trades) sold 15,000 shares of TNDM on 08/12/2019 at an average price of $62.97 a share. Continue reading...
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
In his final "Executive Decision" segment of Mad Money Wednesday night, Jim Cramer also checked in with Kim Blickenstaff, executive chairman at Tandem Diabetes Care , which posted strong earnings last week that sent shares up over 8% before giving back much of those gains by the close. Blickenstaff blamed the sudden reversal in their shares on global uncertainty. Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem.
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
The medical device company got oh-so-close to erasing operating losses in Q2, but second-half growth will finally put the business in the black.
Today we will run through one way of estimating the intrinsic value of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by...
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2019 and updated its financial guidance for the year ending December 31, 2019.
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced it is offering no-cost feature updates for t:slim X2 insulin pump customers in the United States through the end of 2020. “Our ability to provide our customers with remote feature updates exemplifies our Company’s mission to improve the lives of people with diabetes through relentless innovation and revolutionary customer experience,” said John Sheridan, president and CEO of Tandem Diabetes Care.
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019.
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (TNDM) Brian B Hansen (insider trades) sold 13,031 shares of TNDM on 07/11/2019 at an average price of $70.04 a share. Continue reading...
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM): Tandem Diabetes Care, Inc., a medical device company, designs, develops...